BCM
TENX icon

Bourgeon Capital Management’s Tenax Therapeutics TENX Stock Holding History

Bourgeon Capital Management’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2
Closed -$137K – 101
2016
Q4 		$137K Sell
2
-1
-33% -$58.7K 0.09% 86
2016
Q3 		$218K Buy
3
+1
+50% +$78.9K 0.14% 80
2016
Q2 		$168K Hold
2
– – 0.11% 84
2016
Q1 		$114K Hold
2
– – 0.08% 89
2015
Q4 		$182K Buy
2
+1
+100% +$104K 0.12% 85
2015
Q3 		$52K Buy
+1
New +$114K 0.04% 92

Other funds holding TENX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Bourgeon Capital Management's TENX Position: Q1 2017 in Review

Bourgeon Capital Management sold out of Tenax Therapeutics (TENX) in Q1 2017, closing a stake of 2 shares — an estimated $137K sold.

Bourgeon Capital Management first reported a position in TENX in Q3 2015 and held it in 6 quarters. The position peaked at $218K in Q3 2016. 11 funds tracked by Wall St. Rank hold TENX as of Q1 2017.

  • Bourgeon Capital Management reported no remaining Tenax Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Bourgeon Capital Management sold 2 Tenax Therapeutics shares in Q1 2017, an estimated $137K.
  • Bourgeon Capital Management first reported a position in Tenax Therapeutics in Q3 2015 and held it in 6 quarters.
  • Bourgeon Capital Management's Tenax Therapeutics position peaked at $218K in Q3 2016.
  • 11 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2017.

Based on Bourgeon Capital Management's 13F filing for Q1 2017, filed 27 Apr 2017.